SEMA4D and cancer: If the osteoclast Sema4D axis is the only significant contributor to osteoblast suppression, then there may be little bone effect of treatment in patients also receiving anti-osteoclast drugs (bisphosphonates or denosumab), which are the standard of care for cancer bone diseases.